The IRX2 antibody is a tool used to detect and study the Iroquois homeobox 2 (IRX2) protein, a transcription factor belonging to the Iroquois (IRX) gene family. This family, characterized by a conserved homeodomain, plays critical roles in embryonic development, particularly in patterning tissues and organs. IRX2 is involved in regulating gene expression during morphogenesis, cell differentiation, and tissue specification. Research has linked IRX2 to developmental processes such as heart formation, limb development, and nervous system organization. Dysregulation of IRX2 has been implicated in diseases, including cancer, where it may act as either an oncogene or tumor suppressor depending on the context. For instance, altered IRX2 expression has been observed in breast cancer, colorectal cancer, and neuroblastoma, suggesting its potential role in tumor progression or metastasis. The IRX2 antibody is widely utilized in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to analyze protein expression, localization, and interactions in both normal and pathological samples. Its application extends to studying stem cell biology, tissue engineering, and regenerative medicine. Despite its utility, challenges remain in understanding IRX2's precise molecular mechanisms and context-dependent functions. Current studies focus on its regulatory networks, post-translational modifications, and therapeutic targeting potential, making the IRX2 antibody a key reagent in developmental and translational research.